Last Updated
June 2026
If you are researching GLP-1 weight loss medications in 2026, you have almost certainly encountered two very different price points: brand-name medications like Wegovy or Zepbound at $800–$1,600/month, and compounded semaglutide or tirzepatide programs starting at $149–$249/month through telehealth platforms. The active ingredients are the same. The price difference is enormous. Understanding exactly what you are comparing, and what the real tradeoffs are, is essential before you commit to a program.
Shed
Shed offers both name-brand and compounded GLP-1 weight loss medications with integrated coaching, a 2-minute approval assessment, and 10% off your first month.
What Are Brand-Name GLP-1 Medications?
Brand-name GLP-1 and GLP-1+GIP medications approved for weight management include:
- Wegovy (semaglutide 2.4mg weekly, Novo Nordisk), FDA-approved for chronic weight management; clinical trials showed 15–17% average weight loss at 68 weeks
- Ozempic (semaglutide 0.5–2mg, Novo Nordisk), FDA-approved for type 2 diabetes; widely prescribed off-label for weight loss
- Zepbound (tirzepatide 2.5–15mg, Eli Lilly), FDA-approved for chronic weight management; the only approved GLP-1+GIP dual agonist for obesity, with clinical trials showing up to 22.5% weight loss
- Mounjaro (tirzepatide, Eli Lilly), FDA-approved for type 2 diabetes; the branded tirzepatide formulation
Shed
Shed offers both name-brand and compounded GLP-1 weight loss medications with integrated coaching, a 2-minute approval assessment, and 10% off your first month.
Brand-name medications undergo comprehensive FDA review covering safety, efficacy, manufacturing quality, and labeling consistency. They are produced in tightly controlled pharmaceutical facilities under FDA Good Manufacturing Practice (GMP) regulations. The clinical trial data supporting these medications is extensive and peer-reviewed.
What Is Compounded GLP-1?
Compounded GLP-1 refers to semaglutide or tirzepatide formulations prepared by a licensed 503A or 503B compounding pharmacy using active pharmaceutical ingredients (APIs), not the finished brand-name drug. The compounded product contains the same active molecule but is not manufactured by or subject to the same FDA oversight as the branded finished product.
In 2026, two types of compounded GLP-1 are available through telehealth programs:
- Compounded GLP-1 (semaglutide): The same active ingredient as Ozempic and Wegovy, prepared by a licensed compounding pharmacy. Starting at $149/month through major telehealth platforms.
- Compounded GLP-1+GIP (tirzepatide dual agonist): The same active ingredient as Mounjaro and Zepbound. GLP-1+GIP activates both GLP-1 and GIP hormone receptors simultaneously, producing stronger appetite suppression and metabolic effects. Starting at $249/month through telehealth platforms.
GLP-1 vs GLP-1+GIP: Understanding the Difference
One of the most important distinctions in 2026 is between GLP-1 and GLP-1+GIP (dual agonist) medications. Both are available in compounded form through telehealth programs, but they work differently:
| Feature | GLP-1 (Semaglutide) | GLP-1+GIP (Tirzepatide) |
|---|---|---|
| Mechanism | Single agonist (GLP-1 receptor) | Dual agonist (GLP-1 + GIP receptors) |
| Brand equivalents | Ozempic, Wegovy | Mounjaro, Zepbound |
| Average weight loss (clinical) | ~15–17% | ~20–22.5% |
| Compounded starting price (2026) | $149/month | $249/month |
| Weekly dosing | Yes | Yes |
Compounded vs Brand-Name: Full Comparison
| Factor | Brand-Name GLP-1 | Compounded GLP-1 |
|---|---|---|
| FDA Approval | Yes, finished drug product reviewed by FDA | No, preparation from API; not FDA-reviewed for safety or efficacy |
| Manufacturing Standards | FDA GMP pharmaceutical facilities | State-licensed compounding pharmacy (503A or 503B) |
| Monthly Cost (without insurance) | $800–$1,600+/month | $149–$400/month depending on type and platform |
| Insurance Coverage | Some commercial plans; highly variable; prior auth required | Generally not covered |
| HSA/FSA Eligible | Yes | Yes (through licensed telehealth provider) |
| Dosing Flexibility | Fixed standard doses per labeling | Customizable by prescribing clinician |
| Access Without Insurance | Challenging; savings cards available | Straightforward, no prior auth, direct-pay model |
| BNPL Financing | Generally not available | Available (Affirm, Klarna, Afterpay) on most telehealth platforms |
| Clinical Evidence Base | Extensive RCT trial data (STEP, SURMOUNT trials) | Same active ingredient; no independent compounded-specific trials |
How to Evaluate a Compounding Pharmacy
Not all compounding pharmacies operate at the same standard, and quality varies significantly. When evaluating a telehealth program that uses compounded GLP-1, verify:
- FDA registration and state licensure: The pharmacy must be registered with the FDA and licensed by the state board of pharmacy
- 503B vs 503A designation: 503B outsourcing facilities are subject to stricter federal Current GMP (cGMP) oversight than 503A pharmacies, which operate under state oversight only
- PCAB accreditation: Pharmacy Compounding Accreditation Board certification signals adherence to quality standards beyond minimum regulatory requirements
- Third-party testing: Potency, sterility, and endotoxin certificates from independent labs confirm the compound matches the labeled concentration
- Cold chain and storage: Semaglutide and tirzepatide require proper refrigerated storage and shipping protocols to maintain stability
- Regulatory compliance communication: The telehealth platform should proactively update patients on FDA shortage-list status and any regulatory changes
The 2026 Regulatory Landscape
GLP-1 compounding has operated under evolving FDA oversight. The key legal basis for compounding GLP-1 is the FDA drug shortage designation: compounding is legally permitted when a brand-name drug is on the official shortage list. Semaglutide and tirzepatide shortage status has fluctuated since 2023.
In 2025, the FDA removed semaglutide from the shortage list, which resulted in enforcement action against 503A and 503B pharmacies compounding semaglutide for patient-specific prescriptions. Many platforms shifted to tirzepatide or continued semaglutide under specific regulatory pathways. By mid-2026, compounded GLP-1 and GLP-1+GIP programs remain widely available through licensed telehealth providers, though patients should confirm current availability and regulatory status with their chosen platform at enrollment.
Who Should Choose Compounded GLP-1?
Compounded GLP-1 is the practical choice for the majority of patients seeking GLP-1 weight loss treatment in 2026 because:
- Brand-name GLP-1 without insurance costs $800–$1,600+/month, 5–10x more than compounded alternatives
- Insurance prior authorization for weight loss GLP-1 is frequently denied or takes weeks to resolve
- Compounded programs offer flexible BNPL payment options, HSA/FSA eligibility, and competitive monthly rates
- The active ingredient is identical, the clinical evidence base for semaglutide and tirzepatide applies regardless of whether you use the brand-name or compounded version
- 350,000+ patients have been treated through compounded GLP-1 telehealth programs with strong outcomes data
Who Should Choose Brand-Name GLP-1?
Brand-name GLP-1 is the right choice when:
- You have commercial insurance coverage that will pay for Wegovy or Zepbound after prior authorization
- You are injection-averse and want the Wegovy pill (oral semaglutide), available exclusively through platforms like Ro
- You require the regulatory assurance of an FDA-approved finished drug product specifically
- Your prescribing physician recommends brand-name for a specific clinical reason
Cost Comparison: Compounded vs Brand in 2026
| Option | Monthly Cost | Annual Cost | Notes |
|---|---|---|---|
| Compounded GLP-1 (semaglutide) | From $149 | ~$1,788 | No insurance needed; price locked for life |
| Compounded GLP-1+GIP (tirzepatide) | From $249 | ~$2,988 | Stronger dual-agonist mechanism; BNPL available |
| Brand Wegovy (no insurance) | $1,000–$1,600 | $12,000–$19,200 | Manufacturer savings cards may apply |
| Brand Zepbound (no insurance) | $900–$1,300 | $10,800–$15,600 | Eli Lilly savings card available for eligible patients |
Frequently Asked Questions
Is compounded semaglutide the same as Wegovy?
Compounded semaglutide contains the same active molecule, semaglutide, as Wegovy and Ozempic. However, it is not manufactured by Novo Nordisk or under the same FDA oversight process. The FDA has not independently reviewed compounded semaglutide for safety, effectiveness, or quality. Quality depends heavily on the specific compounding pharmacy. From a licensed, FDA-registered pharmacy with third-party testing, compounded semaglutide is clinically appropriate for the same weight loss application.
Is compounded GLP-1 safe?
From reputable, FDA-registered pharmacies with PCAB accreditation and independent potency/sterility testing, compounded GLP-1 is generally considered clinically appropriate for weight loss treatment. The FDA has flagged lower-quality compounders for quality control failures, pharmacy source matters significantly. Patients should confirm their telehealth platform uses a licensed pharmacy and discloses its accreditation status.
What is the difference between GLP-1 and GLP-1+GIP?
GLP-1 medications (semaglutide) work on a single receptor to reduce appetite and regulate blood sugar. GLP-1+GIP medications (tirzepatide) are dual agonists that activate both the GLP-1 and GIP receptors simultaneously, producing stronger appetite suppression and greater average weight loss in clinical trials (up to 22.5% vs 15–17% for GLP-1 alone). GLP-1+GIP programs start at $249/month vs $149/month for GLP-1-only programs.
Why is compounded GLP-1 so much cheaper than brand-name?
Brand-name pricing reflects years of clinical development, the FDA approval process, pharmaceutical-scale manufacturing requirements, and the manufacturer's investment in post-approval pharmacovigilance. Compounding pharmacies produce smaller batches without those development costs. The active ingredient is the same, you are not paying for a different molecule when you choose brand-name, you are paying for the regulated manufacturing process and brand equity.
What happens if compounded GLP-1 becomes unavailable?
If the FDA drug shortage designation changes, compounding restrictions may tighten for specific medications. Reputable telehealth platforms communicate regulatory changes proactively and can often transition patients to alternative compounds (e.g., from semaglutide to tirzepatide) or to branded products if necessary. When evaluating a platform, ask how they handle regulatory changes and what their communication process is for enrolled patients.
Is compounded GLP-1 HSA/FSA eligible?
Yes. Prescription GLP-1 medications obtained through licensed telehealth providers are generally HSA/FSA eligible as qualified medical expenses. Confirm eligibility with your HSA/FSA account administrator for your specific plan and situation.
Can I use BNPL financing for compounded GLP-1?
Yes. Most major compounded GLP-1 telehealth platforms offer 0% interest financing through Affirm, Klarna, or Afterpay. This makes it possible to start treatment without covering the full monthly cost upfront, spreading payments across 3–12 monthly installments.
Sources: FDA on drug compounding
Ready to Start With a Trusted Compounded GLP-1 Program?
TrimRx has served 100,000+ happy customers with a 4.8 Excellent Rating. Compounded GLP-1 starts at $149/month and GLP-1+GIP starts at $249/month, with Lifetime Price Protection that locks in today's price for life, HSA/FSA eligible, and 0% financing available.
Compare GLP-1 Weight Loss Programs →Editor's Choice, Weight Loss
Shed
Shed offers both name-brand and compounded GLP-1 weight loss medications with integrated coaching, a 2-minute approval assessment, and 10% off your first month.
Sources & References
- STEP 1 Trial: Once-Weekly Semaglutide in Adults with Overweight or Obesity- New England Journal of Medicine
- SURMOUNT-1 Trial: Tirzepatide Once Weekly for the Treatment of Obesity- New England Journal of Medicine
- FDA Drug Shortages, Semaglutide and Tirzepatide Status- U.S. Food and Drug Administration
- FDA Guidance on Compounding, 503A and 503B Pharmacies- U.S. Food and Drug Administration
- GLP-1 Receptor Agonists: Mechanism of Action and Clinical Evidence- National Institutes of Health / PubMed Central